降压药依普利酮怎么购买？

India's Lupine Pharmaceutical Company ranks 45th in the world. Lupine Limited is an Indian multinational pharmaceutical company established in 1968, with an estimated net market value of approximately 766.13 billion rupees. Lupine Limited manufactures approximately 5,500 products in the fields of neurology, cardiology, diabetology and other therapeutic areas. Antihypertensive drugs are manufactured by Lupine Pharmaceuticals in India.

The antihypertensive drug eplerenone of India's Lupine Pharmaceuticals is a selective aldosterone receptor antagonist. It only acts on mineralocorticoid receptors and does not act on androgen and progesterone receptors. Eplerenone has a potassium-sparing diuretic effect, can reverse left ventricular hypertrophy, lower blood pressure, and treat primary aldosteronism. Compared with spironolactone, eplerenone can prevent gynecomastia and sexual dysfunction, has a better potassium-sparing diuretic effect, and is mainly used clinically to treat hypertension and heart failure. This drug reaches its peak blood concentration 1.5 hours after taking it, has a half-life of about 4 to 6 hours, and its absorption is not affected by food.

How to buy the antihypertensive drug eplerenone from Lupine Pharmaceuticals in India?

The antihypertensive drug of India's Lupine Pharmaceuticals is only available in India. The channels for patients to purchase the antihypertensive drug eplerenone of India's Lupine Pharmaceuticals are: First, purchasing on behalf of others. Due to the high risk of personal purchasing, we have no way of knowing the authenticity and source of the drugs, so we do not recommend patients to choose this method. Second, you can look for professional overseas medical institutions (such as Medical Companion Travel). Medical Companion Travel is a professional overseas medical service organization that can assist domestic patients to purchase genuine and guaranteed eplerenone without going abroad. For more related inquiries, please contact Medical Companion Travel Service.

Recommended related hot articles: /newsDetail/88355.html